Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31732779 | 0.86 | DPP8 (0.53) | DPP8DPP9DPP4DYRK3CSNK1E | |
| SCHEMBL5608146 | 0.83 | POLB (0.41) | DPP8DPP9POLBNAAAPKM | |
| SCHEMBL20243117 | 0.81 | DPP8 (0.34) | DPP8DPP9DPP4ALDH1A1 | |
| SCHEMBL27356480 | 0.79 | DPP8 (0.41) | DPP8DPP9DPP4POLBNAAA | |
| SCHEMBL5608432 | 0.78 | GRIN2D (0.43) | DPP8DPP9POLBNAAAPKM | |
| SCHEMBL25589902 | 0.78 | DPP8 (0.53) | DPP8DPP9DPP4DYRK3CSNK1E | |
| SCHEMBL3366010 | 0.78 | POLB (0.45) | DPP8DPP9DPP4DYRK3CLK1 | |
| Hydrochloric Acid SCHEMBL27804946 | 0.76 | POLB (0.44) | DPP8DPP9DPP4DYRK3CLK1 | |
| SCHEMBL5179241 | 0.76 | POLB (0.50) | DPP8DPP9POLBNAAAPKM | |
| SCHEMBL3363263 | 0.75 | DPP4 (0.50) | DPP8DPP9DPP4POLBNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569250-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| EP-2247602-B1 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| US-20120295860-A1 | ORGANIC COMPOUNDS | HASSIEPEN ULRICH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-8252751-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-2247602-A2 | ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100256080-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| WO-2009068531-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| EP-1137635-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| EP-1137635-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6166063-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034241-A1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256080-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | DPP8 4/4885DPP9 8/4885DPP4 1/4885 |
| US-20120295860-A1 | ORGANIC COMPOUNDS | DPP4, DPP7, DPP3 | DPP8 4/4885DPP9 8/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.